Anemia In End Stage Renal Disease Study Testing And Investigational Drug Daprodustat Anemia Pill Vs. The Standard Of Care (Aranesp) Injections.
Posted Date: Jan 16, 2018
- Investigator: Shashi Kant
- Type of Study: Drug
The purpose of this study is to test how effective daprodustat (an investigational medicine which has not yet been approved by regulatory agencies such as the United States Food and Drug Administration (FDA)) is compared with epoetin alfa or darbepoetin alfa (which has been approved) (called EPO from here on) to treat your anemia and to see how safely this can be done over a long period of time.
Patients With End Stage Renal Disease Currently On Hemodialysis Or Peritoneal Dialysis For > 90 Days, At Dci Clinics Mcmillan, West Chester Or Western Hills. Currently Receiving Aranesp Injections For Anemia With Stable Hemoglobin Between 8 And 12Mg/Dl At Screening, Adequate Iron Stores. No Recent Cardiovascular Events, No Previous Transplant, Cancer, Active Liver Disease, Other Significant Medical Problems. Women Must Be Willing To Use Adequate Birth Control If Of Child-Bearing Potential.
Erythropoeisis Stimulating Agent, Anemia, Dialysis, Null, Null
For More Information:
Heather J Duncan, Phd